New book by Larry Connors Click here Improve your trading - See how
Mr. Elliot brings over 25 years of experience in the medical device industry. Mr. Elliot joins TYRX from Valam Corp., a privately held company focused on providing laser-based antimicrobial and vascular plaque destruction therapies, where he was President and CEO and remains a Board Director. Prior to Valam, Mr. Elliot was President, COO and Board Director of VistaCare, Inc., a publicly traded hospice care provider. Prior to VistaCare, Mr. Elliot was President, CEO and Board Director of The VASCLIP Company, a privately held medical device company that provides a less invasive surgical alternative to vasectomy. Prior to VASCLIP, Mr. Elliot was the Vice President of Sales and Marketing at Advanced Respiratory, Inc., a privately held company now owned by Hillenbrand Industries, Inc., that sold a proprietary FDA-approved medical device for patients with respiratory issues.
From 1996 to 2001, Mr. Elliot held two senior executive positions (Vice President, Global Marketing of Cardiac Rhythm Management and Director of Corporate Business Development) at St. Jude Medical. In 1987, Mr. Elliot began his career in healthcare executive management at Guidant Corporation, where during the following nine years he held different roles of escalating responsibility and was ultimately the director of Guidant Japan's Cardiac Rhythm Management division. Mr. Elliot earned a Bachelor of Arts in English from Connecticut College and an MBA from the University of Chicago.
"We are thrilled to have David join our management team," said Bill Edelman, President and CEO. "David's experience in the Cardiac Rhythm Management space, as well as his demonstrated track record of achievement in entrepreneurial settings, provides a powerful combination of skills to support the commercialization of our AIGISRx(TM) platform and to advance our forward looking strategies to bring TYRX's unique device/drug products to the market."
"I am excited about joining the TYRX team, which has already launched its first proprietary anti-bacterial device, AIGISRx, has entered a partnership for another, and has a multi-platform pipeline of additional proprietary technologies addressing postsurgical infection and other high cost implant associated morbidities," said Mr. Elliot. "I look forward to adding my business development and marketing experience to the impressive skill set already present at TYRX."
About TYRX, Inc.
TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGISRx(TM) Anti-Bacterial Envelope. AIGISRx CRMD contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in CRMD related endocarditis, including "superbugs" or MRSA. In addition, AIGISRx is intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June, 2008, AIGISRx has been implanted in over 1,200 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.
For more information, please visit www.TYRX.com.
CONTACT Bill Edelman President and Chief Executive Officer TYRX, Inc. 732.246.8676 william@TYRX.com
SOURCE TYRX, Inc.
http://www.TYRX.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
